Cytokine-induced enhancement of autoimmune inflammation in the brain and spinal cord: Implications for multiple sclerosis

Neuropathology and Applied Neurobiology

Volumn 30, Issue 4, 2004, Pages 374-384

  Sun, D ^a,b   Newman, T A ^a   Perry, V H ^a   Weller, R O ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Brain; Cytokine; Experimental allergic encephalomyelitis (EAE); Inflammation; Interferon ; Multiple sclerosis; Tumour necrosis factor

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT CYTOKINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLOOD BRAIN BARRIER; BRAIN REGION; CONTROLLED STUDY; CYTOKINE RELEASE; ENCEPHALITIS; FEMALE; GENE EXPRESSION; HISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY CELL; LYMPHOCYTIC INFILTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROGLIA; MULTIPLE SCLEROSIS; MYELITIS; NERVE FIBER DEGENERATION; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAT; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; AXONS; BRAIN; BRAIN CHEMISTRY; CYTOKINES; ENCEPHALITIS; FEMALE; INTERFERON TYPE II; LYMPHOCYTES; MICROGLIA; MULTIPLE SCLEROSIS; MYELITIS; NERVE DEGENERATION; RATS; RATS, INBRED LEW; SPINAL CORD; STEREOTAXIC TECHNIQUES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4344708352     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2003.00546.x     Document Type: Article

References (43)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-31
2. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-9
3. Prineas JW, McDonald WI, Franklin RJM. Demyelinating disease. In Greenfields Neuropathology. Eds DI Graham, PL Lantos. London: Arnold, 2002; 471-535
4. Vass K, Lassmann H. Intrathecal application of interferon gamma. Progressive appearance of MHC antigens within the rat nervous system. Am J Pathol 1990; 137: 789-800
5. Bansil S, Cook SD, Rohowsky-Kochan C. Multiple sclerosis: immune mechanism and update on current therapies. Ann Neurol 1995; 37: S87-101
6. Raine CS. The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion. Ann Neurol 1994; 36: S61-72
7. Phillips MJ, Needham M, Weller RO. Role of cervical lymph nodes in autoimmune encephalomyelitis in the Lewis rat. J Pathol 1997; 182: 457-64
8. Phillips MJ, Weller RO, Kida S, Iannotti F. Focal brain damage enhances experimental allergic encephalomyelitis in brain and spinal cord. Neuropathol Appl Neurobiol 1995; 21: 189-200
9. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999; 12: 295-302
10. Cserr HF, Harling-Berg CJ, Knopf PM. Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathol 1992; 2: 269-76
11. Okamoto Y, Yamashita J, Hasegawa M, Fujisawa H, Yamashima T, Hashimoto T, Nonomura A, Matsumoto Y, Kida S. Cervical lymph nodes play the role of regional lymph nodes in brain tumour immunity in rats. Neuropathol Appl Neurobiol 1999; 25: 113-22
12. Lake J, Weller RO, Phillips MJ, Needham M. Lymphocyte targeting of the brain in adoptive transfer cryolesion-EAE. J Pathol 1999; 187: 259-65
13. Sun D, Tani M, Newman TA, Krivacic K, Phillips M, Chernosky A, Gill P, Wei T, Griswold KJ, Ransohoff RM, Weller RO. Role of chemokines, neuronal projections, and the blood-brain barrier in the enhancement of cerebral EAE following focal brain damage. J Neuropathol Exp Neurol 2000; 59: 1031-43
14. Widner H, Jonsson BA, Hallstadius L, Wingardh K, Strand SE, Johansson BB. Scintigraphic method to quantify the passage from brain parenchyma to the deep cervical lymph nodes in rats. Eur J Nucl Med 1987; 13: 456-61
15. Feuerstein GZ, Liu T, Barone FC. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc Brain Metab Rev 1994; 6: 341-60
16. Colton CA, Yao J, Keri JE, Gilbert D. Regulation of microglial function by interferons. J Neuroimmunol 1992; 40: 89-98
17. Wang CX, Shuaib A. Involvement of inflammatory cytokines in central nervous system injury. Prog Neurobiol 2002; 67: 161-72
18. Fierz W, Endler B, Reske K, Wekerle H, Fontana A. Astrocytes as antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J Immunol 1985; 134: 3785-93
19. Dore-Duffy P, Balabanov R, Rafols J, Swanborg RH. Recovery phase of acute experimental autoimmune encephalomyelitis in rats corresponds to development of endothelial cell unresponsiveness to interferon gamma activation. J Neurosci Res 1996; 44: 223-34
20. Billiau A. Interferon-gamma: biology and role in pathogenesis. Adv Immunol 1996; 62: 61-130
21. Glabinski A, Krajewski S, Rafalowska J. Tumor necrosis factor-alpha induced pathology in the rat brain: characterization of stereotaxic injection model. Folia Neuropathol 1998; 36: 52-62
22. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-14
23. Anthony DC, Bolton SJ, Fearn S, Perry VH. Age-related effects of interleukin-1 beta on polymorphonuclear neutrophil-dependent increases in blood-brain barrier permeability in rats. Brain 1997; 120: 435-44
24. Sethna MP, Lampson LA. Immune modulation within the brain: recruitment of inflammatory cells and increased major histocompatibility antigen expression following intracerebral injection of interferon-gamma. J Neuroimmunol 1991; 34: 121-32
25. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985; 1: 1313-5
26. Lampson LA. Interpreting MHC class I expression and class I/class II reciprocity in the CNS. reconciling divergent findings. Microsc Res Tech 1995; 32: 267-85
27. Konno H, Yamamoto T, Suzuki H, Yamamoto H, Iwasaki Y, Ohara Y, Terunuma H, Harata N. Targeting of adoptively transferred experimental allergic encephalitis lesion at the sites of wallerian degeneration. Acta Neuropathol (Berl) 1990; 80: 521-6
28. Molleston MC, Thomas ML, Hickey WF. Novel major histocompatibility complex expression by microglia and site-specific experimental allergic encephalomyelitis lesions in the rat central nervous system after optic nerve transection. Adv Neurol 1993; 59: 337-48
29. Schnell L, Fearn S, Schwab ME, Perry VH, Anthony DC. Cytokine-induced acute inflammation in the brain and spinal cord. J Neuropathol Exp Neurol 1999; 58: 245-54
30. Konsman JP, Tridon V, Dantzer R. Diffusion and action of intracerebroventricularly injected interleukin-1 in the CNS. Neuroscience 2000; 101: 957-67
31. Krakowski M, Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol 1996; 26: 1641-6
32. Pagenstecher A, Lassmann S, Carson MJ, Kincaid CL, Stalder AK, Campbell IL. Astrocyte-targeted expression of IL-12 induces active cellular immune responses in the central nervous system and modulates experimental allergic encephalomyelitis. J Immunol 2000; 164: 4481-92
33. Renno T, Taupin V, Bourbonniere L, Verge G, Tran E, De Simone R, Krakowski M, Rodriguez M, Peterson A, Owens T. Interferon-gamma in progression to chronic demyelination and neurological deficit following acute EAE. Mol Cell Neurosci 1998; 12: 376-89
34. Kassiotis G, Pasparakis M, Kollias G, Probert L. TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis. Eur J Immunol 1999; 29: 774-80
35. Korner H, Riminton DS, Strickland DH, Lemckert FA, Pollard JD, Sedgwick JD. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med 1997; 186: 1585-90
36. Rothwell NJ, Relton JK. Involvement of interleukin-1 and lipocortin-1 in ischaemic brain damage. Cerebrovasc Brain Metab Rev 1993; 5: 178-98
37. Blatteis CM. The afferent signalling of fever. J Physiol 2000; 526: 470
38. Eskandari F, Sternberg EM. Neural-immune interactions in health and disease. Ann N Y Acad Sci 2002; 966: 20-7
39. Emsley HC, Smith CJ, Gavin CM, Georgiou RF, Vail A, Barberan EM, Hallenbeck JM, del Zoppo GJ, Rothwell NJ, Tyrrell PJ, Hopkins SJ. An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol 2003; 139: 93-101
40. Craig SR, Leaver HA, Yap PL, Pugh GC, Walker WS. Acute phase responses following minimal access and conventional thoracic surgery. Eur J Cardiothorac Surg 2001; 20: 455-63
41. Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, van Der Meche FG, van Doorn PA, Hintzen RQ. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002; 125: 952-60
42. Buljevac D, Hop WC, Reedeker W, Janssens AC, Van Der Meche FG, Van Doom PA, Hintzen RQ. Self reported stressful life events and exacerbations in multiple sclerosis: prospective study. Bmj 2003; 327: 646
43. Lassmann H, Vass K. Are current immunological concepts of multiple sclerosis reflected by the immunopathology of its lesions? Springer Semin Immunopathol 1995; 17: 77-87